Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, +27

New England Journal of Medicine

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

Robert L. Coleman, Amit M. Oza, Domenica Lorusso, +112

The Lancet

Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment +5

Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study

Susan M. Domchek, Sophie Postel‐Vinay, Seock‐Ah Im, +22

The Lancet Oncology

Phase 1/2Breast OncologyOncologyBasket StudyPathology +6

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

I. Ray-Coquard, Alexandra Léary, Sandro Pignata, +26

Annals of Oncology

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial

Olivier Trédan, Qing Wang, Daniel Pissaloux, +34

Annals of Oncology

MedicinePatient SelectionCancer ManagementPathologyMolecular-based Recommended Therapies +8

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, +116

The Lancet

OncologyCervical CancerMetronomic TherapyPathologyRecurrent Cervical Cancer +4

Genomics to select treatment for patients with metastatic breast cancer

Fabrice André, Thomas Filleron, Maud Kamal, +36

Nature

Metastatic Breast CancerBreast OncologyTumor HeterogeneityMedicinePathology +7

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Thomas Bachelot, Thomas Filleron, Ivan Bièche, +29

Nature Medicine

Metastatic Breast CancerBreast OncologyMedicineImmunologyPathology +5

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i> -Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma Dean, José Alejandro Pérez Fidalgo, +26

Clinical Cancer Research

Pathological Response to Neoadjuvant Chemotherapy: A New Prognosis Tool for the Curative Management of Peritoneal Colorectal Carcinomatosis

Guillaume Passot, Benoît You, Gilles Boschetti, +8

Annals of Surgical Oncology

Surgical OncologyGastrointestinal OncologyMedicineCancer ManagementSurgical Pathology +12